| Literature DB >> 26960976 |
Emmanuel Griessinger1, Fernando Anjos-Afonso2, Jacques Vargaftig3, David C Taussig4, François Lassailly3, Thomas Prebet5, Véronique Imbert6, Marielle Nebout6, Norbert Vey5, Christian Chabannon5, Andrew Filby7, Frederic Bollet-Quivogne8, John G Gribben4, Jean-François Peyron6, Dominique Bonnet9.
Abstract
Acute myeloid leukemia (AML) is sustained by a subpopulation of rare leukemia-initiating cells (LIC) detected in the xenograft assay by their capacity to self-renew and to generate non-LICs in vivo The xenotransplantation model captures functional properties of LICs that have clinical prognostic value. However, the long duration of this in vivo assay has hampered its use as a prognostic tool. Here, we show, using an ex vivo coculture system, that intermediate and poor risk AML patient samples at diagnosis have a 5 to 7 times higher frequency of leukemic long-term culture-initiating cells (L-LTC-IC) compared with the good risk group. We defined a fluorescence dilution factor (FDF) parameter that monitors sample proliferation over 1 week and established a strong correlation of this parameter with the L-LTC-IC frequency. A higher FDF was found for poor prognostic AMLs or for samples capable of engrafting NSG mice compared with good risk AMLs or nonengrafters. Importantly, FDF could classify normal karyotype intermediate risk patients into two groups with a significant difference in their overall survival, thus making this nongenetic and non-in vivo approach a new clinically relevant tool for better diagnosis of AML patients. Cancer Res; 76(8); 2082-6. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Year: 2016 PMID: 26960976 DOI: 10.1158/0008-5472.CAN-15-2063
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701